Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 27 April 1984:
Vol. 224. no. 4647, pp. 395 - 396
DOI: 10.1126/science.6546809
Prev | Table of Contents | Next

Articles

Science, Vol 224, Issue 4647, 395-396
Copyright © 1984 by American Association for the Advancement of Science

articles

Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide

LR Watkins, IB Kinscheck, and DJ Mayer

Exogenous cholecystokinin selectively antagonizes opiate analgesia, which suggests that endogenous cholecystokinin may act physiologically as an opiate antagonist and may play a role in opiate tolerance. The use of the selective cholecystokinin antagonist proglumide provided a test of these hypotheses in rats that were either inexperienced with or tolerant to opiates. Proglumide potentiated analgesia produced by morphine and endogenous opiates and seemed to reverse tolerance. These results suggest that endogenous cholecystokinin systems oppose the action of opiates.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Cholecystokinin in the Rostral Ventromedial Medulla Mediates Opioid-Induced Hyperalgesia and Antinociceptive Tolerance.
J. Y. Xie, D. S. Herman, C.-O. Stiller, L. R. Gardell, M. H. Ossipov, J. Lai, F. Porreca, and T. W. Vanderah (2005)
J. Neurosci. 25, 409-416
   Abstract »    Full Text »    PDF »
Protein Kinase C Activation Enhances Morphine-Induced Rapid Desensitization of {micro}-Opioid Receptors in Mature Rat Locus Ceruleus Neurons.
C. P. Bailey, E. Kelly, and G. Henderson (2004)
Mol. Pharmacol. 66, 1592-1598
   Abstract »    Full Text »    PDF »
Neural Basis for the Hyperalgesic Action of Cholecystokinin in the Rostral Ventromedial Medulla.
M. M. Heinricher and M. J. Neubert (2004)
J Neurophysiol 92, 1982-1989
   Abstract »    Full Text »    PDF »
Circuitry Underlying Antiopioid Actions of Cholecystokinin Within the Rostral Ventromedial Medulla.
M. M. Heinricher, S. McGaraughty, and V. Tortorici (2001)
J Neurophysiol 85, 280-286
   Abstract »    Full Text »    PDF »
Acute Tolerance to Continuously Infused Alfentanil: The Role of Cholecystokinin and N-Methyl-D-Aspartate-Nitric Oxide Systems.
I. Kissin, C. A. Bright, and E. L. Bradley Jr. (2000)
Anesth. Analg. 91, 110-116
   Abstract »    Full Text »    PDF »
Effects of Spinal Cholecystokinin Receptor Antagonists on Morphine Antinociception in a Model of Visceral Pain in the Rat.
A. E. Friedrich and G. F. Gebhart (2000)
J. Pharmacol. Exp. Ther. 292, 538-544
   Abstract »    Full Text »
Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions.
D. J. Mayer, J. Mao, J. Holt, and D. D. Price (1999)
PNAS 96, 7731-7736
   Abstract »    Full Text »    PDF »
Cotreatment with Racemic Fenfluramine Inhibits the Development of Tolerance to Morphine Analgesia in Rats.
R. H. Arends, T. G. Hayashi, T. J. Luger, and D. D. Shen (1998)
J. Pharmacol. Exp. Ther. 286, 585-592
   Abstract »    Full Text »
Cholecystokinin antianalgesia: safety cues abolish morphine analgesia.
E. Wiertelak, S. Maier, and L. Watkins (1992)
Science 256, 830-833
   Abstract »    PDF »
Recent advances in the physiology and pharmacology of pain: plasticity and its implications for clinical analgesia.
A. H. Dickenson (1991)
J Psychopharmacol 5, 342-351
   Abstract »    PDF »
Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors.
C. Dourish, W Rycroft, and S. Iversen (1989)
Science 245, 1509-1511
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)